SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
KMTS reported First Quarter Fiscal 2027 (ended July 31, 2026) results. The stock moved +4.7% on the print.
KMTSearnings

Kestra Medical Technologies, Ltd. (KMTS) Q1 FY2027 earnings

September 15, 2026 · SharpeIQ Research Desk

Reported results

  • Revenue of $31.0 million in F1Q27, an increase of 60% compared to the prior year period.
  • Gross margin expanded to 56.5% in F1Q27 compared to 45.7% in the prior year period.
  • GAAP net loss was $44.1 million compared to GAAP net loss of $25.8 million in the prior year period.
  • Adjusted operating expenses (non-GAAP) were $44.2 million compared to $30.3 million in the prior year period.
  • Adjusted EBITDA loss (non-GAAP) was $24.0 million compared to an adjusted EBITDA loss of $19.4 million in the prior year period.
  • Cash and cash equivalents, and investments totaled $244.7 million as of July 31, 2026.

Guidance

  • FY27 revenue guidance increased to $141 million, representing growth of 48% compared to FY26.

Notes

The company increased FY27 revenue guidance from prior guidance of $137 million. GAAP net loss includes a loss on extinguishment of debt of $6.3 million in the current quarter.

Price and volatility reaction

The stock moved +4.7% on the print. No front-expiry chain was on file, so there is no straddle expected move.

MeasureValueBasis
Close before release24.062026-09-14
Close after release25.182026-09-15
Realised move+4.7%close to close
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-09-14 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →